On August 11, 2025, 180 Life Sciences Corp. announced the closing of a private offering of approximately $156 million aggregate principal amount of senior secured convertible notes due 2028. The notes were sold to an institutional investor on August 8, 2025.
The net proceeds from this convertible note offering are intended to be used to purchase more Ether (ETH), further expanding the company's newly announced ETH treasury strategy. This financing strengthens the company's balance sheet for its new focus.
The Convertible Notes will not accrue interest for the first six months, after which they will accrue at a rate of four percent per annum. They are convertible into shares of common stock at the option of the holder at a conversion price of $3.445 per share, subject to a one-time downward reset.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.